TRVI · XBRL financial data

Trevi Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TRVI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	22,328	22,984	19,834	23,683	39,377	33,478
General and administrative	10,161	9,492	10,073	10,240	12,147	15,850
Total operating expenses	32,489	32,476	29,907	33,923	51,524	49,328
Operating income (loss)	(32,489)	(32,476)	(29,907)	(33,923)	(51,524)	(49,328)
Interest income	—	—	—	4,748	3,602	6,536
Interest expense	456	1,202	1,163	391	4	0
Other income (expense)	—	(375)	289	469	(15)	(31)
Income tax expense (benefit)	(18)	(21)	(36)	(32)	(30)	(64)
Net income (loss)	(32,758)	(33,940)	(29,152)	(29,065)	(47,911)	(42,759)
Earnings per share, basic USD per share	—	(1.49)	(0.45)	(0.29)	(0.47)	(0.32)
Earnings per share, diluted USD per share	—	(1.49)	(0.45)	(0.29)	(0.47)	(0.32)
Weighted average shares, basic thousands of shares	—	22,841	64,542	99,033	101,972	134,747
Weighted average shares, diluted thousands of shares	—	22,841	64,542	99,033	101,972	134,747

† Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (TRVI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	45,001	36,830	12,589	32,397	34,097	18,914
Marketable securities	—	—	107,921	50,574	73,525	169,346
Prepaid and other current assets	1,268	—	—	—	—	—
Total current assets	46,269	37,957	122,616	87,547	109,428	191,656
Property and equipment, net	103	53	170	216	157	178
Right-of-use asset	227	131	24	1,137	915	677
Total assets	47,131	38,475	123,015	89,403	110,900	193,439
Accounts payable	2,016	2,849	2,857	1,809	3,414	3,911
Accrued liabilities	3,426	3,808	3,518	3,709	6,810	5,531
Total current liabilities	5,555	12,724	13,400	5,824	10,509	9,749
Lease liability, non-current	144	24	2	1,001	747	446
Total liabilities	19,849	21,400	15,556	6,856	11,256	10,195
Accumulated deficit	(146,977)	(180,917)	(210,069)	(239,134)	(287,045)	(329,804)
Total stockholders' equity	27,282	17,075	107,459	82,547	99,644	183,244
Total liabilities and equity	47,131	38,475	123,015	89,403	110,900	193,439
Common shares outstanding (cover page) thousands of shares	19,914	30,806	60,045	68,960	96,682	128,397

† Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (TRVI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(32,758)	(33,940)	(29,152)	(29,065)	(47,911)	(42,759)
Stock-based compensation	2,417	2,543	2,327	2,247	3,588	5,185
Depreciation and amortization	—	—	43	123	147	144
Net cash from operating activities	(29,000)	(28,946)	(28,175)	(31,710)	(38,256)	(42,089)
Purchases of property and equipment	32	—	159	137	35	12
Net cash from investing activities	(32)	—	(107,373)	59,428	(21,528)	(94,107)
Proceeds from long-term debt	14,000	—	—	—	—	—
Repayments of long-term debt	—	—	5,833	—	—	—
Net cash from financing activities	16,720	20,775	111,307	(7,910)	61,484	121,013
Net change in cash	(12,312)	(8,171)	(24,241)	19,808	1,700	(15,183)

† Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Amphastar Pharmaceuticals	223,614	183,903	51,324*	42.5M	—	Q2 FY26 10-QJun 30, 2026
Anaptysbio	133,826	27,488*	(26,640)*	29.9M	6.2 quarters	Q4 FY26 10-KTJun 30, 2026
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	110,768	99,313	(60,841)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.